Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
258.3 EUR | +0.35% | -0.15% | -10.13% |
05-21 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
05-21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
Sales 2024 * | 19.8B 2.88B 2.65B 3.92B | Sales 2025 * | 23.62B 3.43B 3.16B 4.68B | Capitalization | 125B 18.17B 16.73B 24.74B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 679M 626M 925M | Net income 2025 * | 6.61B 962M 886M 1.31B | EV / Sales 2024 * | 5 x |
Net cash position 2024 * | 25.9B 3.77B 3.47B 5.13B | Net cash position 2025 * | 32.35B 4.7B 4.33B 6.41B | EV / Sales 2025 * | 3.92 x |
P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.5
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | +0.35% | ||
1 week | -0.15% | ||
1 month | +0.04% | ||
3 months | +1.45% | ||
6 months | -9.15% | ||
Current year | -10.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 258.3 | +0.86% | 21 |
24-05-29 | 256.1 | -0.19% | 251 |
24-05-28 | 256.6 | -0.31% | 15 |
24-05-27 | 257.4 | -0.50% | 40 |
24-05-24 | 258.7 | -3.69% | 41 |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 03:51 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock